Does technology licensing authorise treatment?
No. IP licensing and clinical authorisation are distinct. Intended use, evidence, quality systems and local regulatory requirements need separate review.

From a clear explanation to evidence and a concrete cooperation brief.
Open any image at full size. Research pictures, original schematics and generated concepts are labelled separately; none is an Aurelia patient outcome.
Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.

Confocal image of an OCA1A research model. OCT4 is red, SSEA4 green and nuclei blue; this is not a treatment result.
保留完整画幅和原有标注,仅等比例缩小并转WebP;原始文件同时保留。

Primary-culture morphology from different human umbilical-cord regions. A laboratory comparison, not clinical efficacy data.
保留完整画幅和原有标注,仅等比例缩小并转WebP;原始文件同时保留。
Blood-forming stem cells, MSCs and pluripotent-cell-derived products have distinct uses and evidence. We separate education, published outcomes and institutional cooperation so the details can be assessed.
Understand the cells, the different technologies and the route from laboratory to clinical care.
Read the full page →02Published individual cases and study cohorts, with administration, follow-up and limitations shown together.
Read the full page →03Define a specific institutional project before discussing execution or commercial terms.
Read the full page →04A practical diligence and contracting framework, with the intended use and ownership clearly separated.
Read the full page →05Explore a clinic project with qualified local partners, defining clinical scope before technology or investment commitments.
Read the full page →06Technical cooperation, licensing terms and clinic planning are discussed privately against a specific institutional brief.
Read the full page →Joint research, licensing, process transfer and clinic planning need different scopes. Start with your institution, region, stage and goal. Review science, rights, quality and local permissions before execution.
Cooperation models & requirementsNo. IP licensing and clinical authorisation are distinct. Intended use, evidence, quality systems and local regulatory requirements need separate review.